Vericel Reports 1Q19 MACI Revenue of $16.6MM, +37% vs. 1Q18

Vericel reports 1Q19 MACI revenue of USD $16.6MM, +37% vs. 1Q18.

Biopsy and implant trends indicate that MACI is on track to potentially exceed previous guidance
The company provided revised guidance for MACI and Epicel combined, raising it to $100MM to $114MM, up from $108MM to $112MM; MACI is expected to account for at least $90MM...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us